FDA approves Sanofi and Regeneron’s Dupixent for bullous pemphigoid
The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults…
Dermatology
-
-
‘Dupixent-fuelled’ atopic dermatitis market sales to hit $22.4bn by 2033
The global atopic dermatitis (AD) market is poised to reach $22.4bn in drug sales within the decade, buoyed by the…
-
Ascletis’s daily acne tablet set for China review after Phase III win
Sagimet Bioscience’s denifanstat, a one-daily pill for the treatment of acne, has succeeded in a Phase III trial, with the…
-
Eligo Bioscience secures grant to advance topical gene delivery platform
Biotechnology company Eligo Bioscience has obtained a $5m grant from the French Government to expedite the development and upscaling of…
-
Sanofi and Regeneron’s dupilumab approved by FDA for urticaria
Sanofi and Regeneron's fully human monoclonal antibody Dupixent (dupilumab) has gained approval from the US Food and Drug Administration (FDA)…
-
Alumis and Kaken sign agreement in Japan to develop ESK-001
Alumis and Kaken Pharmaceutical have entered a partnership and licensing agreement for the development, manufacture and commercialisation of the former’s…
-
Menarini to enhance BPDCN detection with VisualDx’s link
The Menarini Group, along with its subsidiary Stemline Therapeutics, has announced a partnership with VisualDx to enhance the detection of…
-
Galderma enters fierce European atopic dermatitis market with Nemluvio approval
Galderma has won approval from the European Commission (EC) for subcutaneous injection Nemluvio (nemolizumab) for the treatment of atopic dermatitis…
-
Vanda and AnaptysBio link for generalised pustular psoriasis therapy
Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the fully humanised immunoglobulin G4…
-
FDA approves Galderma’s Nemluvio to treat atopic dermatitis
The US Food and Drug Administration (FDA) has approved Galderma's monoclonal antibody, Nemluvio (nemolizumab), for individuals aged 12 years and…
